The content here is for informational purposes only, should not be taken as legal business tax or investment advice or be used to evaluate any investment or security and is not directed at any investors or potential investors in any A16Z fund.

For more details, please see A16Z.com slash disclosures.

Hi, and welcome to the A16Z podcast. This episode of the podcast discusses

the business of health care, the challenges and opportunities for new businesses that combine

tech, people, and data to address health care needs. It was recorded at our inaugural

A16Z event late last year and is moderated by general partner Vijay Pande, who starts off the conversation.

The next voice you'll hear will be Sean Duffy, CEO of O'Mada, followed by Accolade CEO,

Rajiv Singh.

Hi, good afternoon.

We were talking actually about what would be a good way to emphasize the cost and the challenges

that we're dealing with here.

Sean made a great point that Starbucks spends more on health care than spends on coffee beans.

Granted, those coffee beans are marked up, but still, it's a dramatic cost.

And so the question is, what can we do about it?

And, you know, there's a traditional sort of biotech approach for handling things.

And the companies that we have up here represented are really taking different approaches.

And so we want to dig into that.

One of the appeal about both of your companies is that there's the opportunity in principle to decrease cost and increase care, the quality of care.

And, you know, on the surface, that sounds like bullshit.

I mean, how is,

how is that possible? Usually you have to choose one or the other. It's funny. I think the most

transformative healthcare innovations of our era will all fit that rubric. And I think it's very

...